Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $2,707,800.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at approximately $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, December 31st, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $78.06, for a total transaction of $2,341,800.00.
• On Monday, December 8th, Nello Mainolfi sold 100,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.17, for a total value of $8,917,000.00.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $91.35 on Friday. The firm has a market capitalization of $6.57 billion, a PE ratio of -24.82 and a beta of 2.21. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $103.00. The stock’s 50 day moving average price is $78.52 and its 200 day moving average price is $65.26.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 34.12%. The firm had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter last year, the company posted ($0.88) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KYMR shares. HC Wainwright lifted their target price on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. BTIG Research cut their target price on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a research report on Thursday. B. Riley Financial increased their target price on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Finally, Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $117.60.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its stake in Kymera Therapeutics by 340.4% during the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. AlphaQuest LLC acquired a new position in Kymera Therapeutics in the second quarter worth $222,000. Finally, Jennison Associates LLC increased its stake in Kymera Therapeutics by 49.4% during the second quarter. Jennison Associates LLC now owns 825,025 shares of the company’s stock valued at $36,004,000 after purchasing an additional 272,739 shares during the last quarter.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.